Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Download PDF Copy

Reviewed

Portola Pharmaceuticals, Inc.Dec 6 2010

Portola Pharmaceuticals, Inc. today announced the presentation of preclinical study results for its novel Syk and JAK inhibitor program at the American Society of Hematology's 52nd Annual Meeting and Exposition. Portola's novel Syk and JAK inhibitors are in development to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Poster Presentation Details

Specific Inhibition of Syk Suppresses Leukocyte Immune Function and Alleviates Inflammation In Rodent Models of Rheumatoid Arthritis

Presenter: Greg Coffey, Ph.D., Portola Pharmaceuticals
Poster Session: Lymphocytes, Lymphocyte Activation and Immunodeficiency, Including HIV and Other Infections: Poster I
Date: Saturday, December 4, 5:30 - 7:30 p.m. ET
Location: Hall A3/A4 (Orange County Convention Center)
Poster Board I-707

P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity in Primary CLL Cells and is Synergistic with Fludarabine at Low Concentrations

Presenter: Stephen Spurgeon, M.D., Oregon Health & Science University Knight Cancer Institute
Poster Session: Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster I
Date: Sunday, December 5, 6:00 - 8:00 p.m. ET
Location: Hall A3/A4 (Orange County Convention Center)
Poster Board II-719

Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia

Presenter: Jan Burger, M.D., Ph.D., MD Anderson Cancer Center
Poster Session: CLL - Biology and Pathophysiology, excluding Therapy: Poster III
Date: Monday, December 6, 6:00 - 8:00 p.m. ET
Location: Hall A3/A4 (Orange County Convention Center)
Poster Board III-383

Sub-Optimal Inhibition of Thrombus Formation by Aspirin (as measured by RTTP analysis) in Primary Thrombocythemia